Bibliographys
- LIPTON A, ALI SM, LEITZEL K et al.:Elevated HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. I. Chit. Oncol. (2002) 20:1467–1472.
- DE LAURENTIIS M, ARPINO G, MASSARELLI E et al.: HERZ as a predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): a metanalysis of published studies. Breast Cancer Res. Treat. (2002) 70:S68. Abstract 233.
- ELLIS MJ, COOP A, SINGH B et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erb B 2 positive, oestrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. CM]. Oncol. (2001) 19:3808–3816.
- •• A trial suggesting relative clinical resistanceof patients with HER2-positive cancer to tamoxifen compared with letrozole.
- LIPTON A, ALI SM, LEITZEL K et al.: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Clin. Oncol. (2003) 21:1967–1972.
- OSBORNE CK, BARDOU V, TORSTEN A et al.: Role of the oestrogen receptor co-activator A1B1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. " Natl. Cancer Inst. (2003) 95:353–361.
- • An important study suggesting a possible mechanism for resistance to tamoxifen in HER2-positive breast cancer.
- FISHER B, BRYANT J, WOLMARK N et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Cilia. Oncol. (1998) 16:2672–2685.
- WOLFF AC, DAVIDSON NE: Primary systemic therapy in operable breast cancer. Clin. Oncol. (2000) 18:1558–1569.
- ELLIS P, SMITH I, ASHLEY S et al.: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. (1998) 16:107–114.
- KUERER HM, NEWMAN LA, SMITH TL et al.: Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. (1999) 17:460–469.
- BURSTEIN HJ, HARRIS LN, GELMAN R et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HERZ overexpressing stage II or III breast cancer: A pilot study. J. Clin. Oncol. (2003) 21:46–53.
- • First study demonstrating the use of trastuzumab in combination with chemotherapy in the neoadjuvant setting.
- MOLUCON C, VANLEMMENS L, CHOLLET P et al: Pathological complete response with neoadjuvant (NA) chemotherapy (trastuzumab (T) and docetaxel (D)) in HERZ positive (3+) locally advanced (LA) breast cancer (BC) patients. Breast Cancer Res. Treat. (2003) 82:S59. Abstract 253.
- SATALOFF DM, MASON BA, PRESTIPINO AJ, SEINIGE UL, LIEBER CP, BALOCH Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.' Am. Coll. Surg. (1995) 180:297–306.
- HUDIS C, SEIDMAN A, PATON V et al.: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res. Treat. (1998) 50:S232. Abstract 24.
- Criteria Committee of the NYHA: Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (7t17 edit). Little Brown, Boston, USA (1973).
- SEIDMAN A, HUDIS C, PIERRI MK et al.: Cardiac dysfunction in the trastuzuamb clinical trials experience. Chit. Oncol. (2002) 20:1215–1221.
- TRIPATHY D, SEIDMAN A, HUDIS C et al.: Effect of cardiac dysfunction on treatment outcome in the Herceptin pivotal trial. Breast Cancer Res. Treat. (2001) 69:S75. Abstract 525.
- PEREZ EA, RODEHEFFER R: Clinical cardiac tolerability of trastuzumab. J. Chit. Oncol. (2004) 22:322–329.
- LEE KF, SIMON H, CHEN H et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 378:394–398.
- ERICKSON SL, O'SHEA KS, GHABOOSI N et al: ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2 and heregulin-deficient mice. Development (1997) 124:4999–5011.
- BRITSCH S, LI L, KIRCHHOFF S et al.: The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for the development of the sympathetic nervous system. Genes Dev. (1998) 12:1825–1836.
- STRASSER F, BETTICHER DC, SUTER TM: Trastuzumab and breast cancer. N Engl. J. Med. (2001) 345:996.
- CRONE SA, ZHAO YY, FAN L et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. (2002) 8:459–465.
- SINGAL PK, DEALLY CM, WEINBERG LE: Subcellular effects of adriamycin in the heart: a concise review. J. MM. Cell. Cardiol. (1987) 19:817–828.
- ROCHE 2001: Herceptin product monograph. Gardiner-Caldwell Communications Ltd, Macclesfield, Chesire, UK.